Optimization of peripheral blood stem cell collection by leukopheresis: Interaction between economic and clinical assessment of an innovation

International Journal of Technology Assessment in Health Care

Volumn 15, Issue 1, 1999, Pages 161-172

  Le Corroller, Anne Gaëlle ^a   Moatti, Jean Paul ^a   Chabannon, Christian ^a   Faucher, Catherine ^a   Fortanier, Cécile ^a   Ladaique, Patrick ^a   Blache, Jean Louis ^a   Novakovitch, Gisèle ^a   Maraninchi, Dominique ^a   Blaise, Didier ^a  

^a NONE

Author keywords

Cost; Economics; Hematopoietic Stem Cell Collection; Optimization

Indexed keywords

AUTOTRANSPLANTATION; BIOMEDICAL TECHNOLOGY ASSESSMENT; CELL SELECTION; CELL SEPARATION; COST EFFECTIVENESS ANALYSIS; GOOD LABORATORY PRACTICE; HEMATOPOIETIC STEM CELL; HUMAN; LEUKAPHERESIS; REVIEW; STEM CELL TRANSPLANTATION;

BONE MARROW TRANSPLANTATION; COSTS AND COST ANALYSIS; FRANCE; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKAPHERESIS; NEOPLASMS; SENSITIVITY AND SPECIFICITY; STATISTICS, NONPARAMETRIC; TRANSPLANTATION, AUTOLOGOUS;

EID: 0032936014     PISSN: 02664623     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0266462399152450     Document Type: Review

References (30)

1. Ager, S., Scott, M. A., & Mahendra, P. Peripheral blood stem cells transplantation after high dose therapy in patients with malignant lymphoma: A retrospective comparison with autologous bone marrow transplantation. Bone Marrow Transplantation 1995, 16, 79-83.
2. Auquier, P., Macquart-Moulin, G., & Moatti, J. P. Comparison of anxiety, pain and discomfort in two procedures of hematopoietic stem cell collection: Leukopheresis and bone marrow harvest. Bone Marrow Transplantation. 1995, 16, 541-47.
3. Bloom, B. S., & Fendrick, A. M. Timing and timeliness in medical care evaluation. PharmacoEconomics. 1996, 9, 183-87.
4. Champlin, E. Peripheral blood progenitor cells: A replacement for marrow transplantation? Seminars in Oncology. 1996, 23(suppl. 4), 15-21.
5. Dercksen, M. W., Rodenhuis, S., & Dirkson, M. K. A. Subsets of CD34+ cells and rapid haematopoietic recovery after peripheral-blood stem-cell transplantation. Journal of Clinical Oncology. 1995, 13, 1922-32.
6. Dickersin, K., & Herxheimer, A. The quality of medical evidence: Is it good enough? International Journal Techno Assessment in Health Care. 1996, 12, 187-89.
7. Drummond, M., & Stoddart, G. Economic analysis and clinical trials. Controlled Clinical Trials 1984, 5, 115-28.
8. Eddy, D. M., & Billings, J. The quality of medical evidence: Implications for quality of care. Health Affairs 1988, Spring, 20-32.
9. Eisenberg, J. M. New drug and clinical economics: Analysis of cost-effectiveness in the assessment of pharmaceutical innovations. Review of Infectious Disease 1984, 6, S905-09.
10. Evans, R. G. Supplier-induced demand, some empirical evidence and implications. In M. Perlmen (ed.). The economics of health and medical care. London: Macmillan, 1974.
11. Faucher, C., Le Corroller, A., & Blaise, D. Comparison of G-CSF primed peripheral blood progenitor and bone marrow autotransplantations: Clinical assesment and cost-effectiveness study. Bone Marrow Transplantation 1994, 14, 895-901.
12. Faucher, C., Le Corroller, A. G., Chabannon, & C. Autologous transplantation of blood stem cells mobilized with G-CSF alone in 93 patients with malignancies: The number of CD34+ cells is the only factor predicting both granulocyte and platelet recovery with G-CSF primed peripheral blood progenitor cells (PBPC). Journal of Haematotherapy 1997, 5, 663-70.
13. Gelijns, A. C. Medical innovation at the crossroad. In A. C. Gelijns (ed.), Modern methods of clinical investigation, vol. 1. Washington DC: National Academy Press, 1990.
14. Gelijns, A. C. Medical innovation at the crossroad. In A. C. Gelijns & E.A. Halm (eds.), The changing economics of medical technolgy, vol. 2. Washington DC: National Academy Press, 1991.
15. Gianni, A. M., Sienna, S., & Bregni, M. Granulocyte-macrophage colony-stimulating factor to harvest circulating hmatopoietic stem cells for autotransplantation. Lancet 1989, 2, 580-84.
16. Gradishar, W. J., Tallman, M. S., & Abrams, J. S. High-dose chemotherapy for breast cancer. Annals of Internal Medicine, 1996, 125, 599-604.
17. Gratwohl, A., Hermans, J., & Baldomero, H. Hematopoietic precursor cell transplants in Europe: Activity in 1994. Report from the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplantation, 1996, 17, 137-48.
18. Halm, E. A.,& Gelijns, A. C. An introduction to the changing economics of technological innovation in medicine. In A. C. Gelijns & E. A. Halm (eds.), The changing economics of medical technology, vol. 2. Washington DC: National Academy Press, 1991, 1-20.
19. Hartmann, O., Le Corroller, A. G., & Blaise, D. Peripheral blood stem cells and bone marrow transplantation for solid tumors and lymphomas: Hematologic recovery and costs. A randomized controlled trial. Annals of Internal Medicine, 1997, 126, 600-07.
20. Hyde, C. J. Using the evidence: A need for quantity, not quality? International Journal of Technology Assessment in Health Care, 1996, 12, 280-87.
21. Le Corroller, A. G., Faucher, C., & Aupérin, A. Autologous blood stem cells transplantation versus autologous bone marrow transplantation for adult and children with nonleukemic malignant disease: A randomized economic study. PharmacoEconomics, 1997, 11, 454-63.
22. Schmitz, N., Linch, D. C., & Dreger, P. Randomised trial of filgrastim mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 1995, 347, 353-57.
23. Sheridan, W. P., Begley, C. G., & Juttner, C. A. Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet, 1992, 339, 640-44.
24. Siena, S., Bregni, M., & Brando, B. Flow cytometry for clinical estimation of circulating hematopoietic progenitors for autologous transplantation in cancer patients. Blood, 1991, 77, 400-09.
25. Smith, A. M., & Keating, A. Peripheral blood progenitor cell transplantation: Clinical, practical and economic considerations. Journal of Hematotherapy, 1994, 3, 331-48.
26. Statistical Processor for Social Sciences, user's guide. S.P.S.S release 6.0, 1993.
27. Uyl-de Groot, C. A., Richel, D. J., & Rutten, F. F. H. Peripheral blood progenitor cell transplantation mobilised by r-metHuG-CSF (filgrastim); A less costly alternative to autologous bone marrow transplantation. European Journal of Cancer, 1994, 30A, 1631-35.
28. Viens, P., Janvier, M., & Fabbro, M. Outpatient high dose intensity doxorubicine cyclophosphamide 5FU with Rh-GCSF and stem cell support (BSC) for inflammatory breast cancer: Pathologic response rate toxicity, quality of life and cost analysis. A French national study (PEGASE 2). Denver, CO: American Society of Clinical Oncology, 1997.
29. Wennberg, J. E. Improving the medical decision making process. Health Affairs, 1988, Spring, 99-106.
30. Wennberg, J. E. Innovation and the policies of limits in a changing health care economy. In A. E. Gelinjs (ed.), Technology and health care in an area of limits. Washington DC: Institute of Medicine, National Academy Press, 1992.